Lipocine phase 3 data for LPCN 1154 accepted for ASCP meeting presentation

May 19, 2026 8:01 AM

Lipocine Inc. (NASDAQ: LPCN) announced that its Phase 3 clinical data for LPCN 1154 have been accepted for oral and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found